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A B S T R A C T
Purpose: This study was designed to find realistic cut-offs of the delays predicting outcome after
generalized convulsive status epilepticus (GCSE) and serving protocol streamlining of GCSE patients.
Method: This retrospective study includes all consecutive adult (>16 years) patients (N = 70) diagnosed
with GCSE in Helsinki University Central Hospital emergency department over 2 years. We defined ten
specific delay parameters in the management of GCSE and determined functional outcome and mortality
at hospital discharge. Functional outcome was assessed with Glasgow Outcome Scale (GOS1-3 for poor
outcome, GOS > 3 for good outcome) and also defined as condition relative to baseline (worse-than-
baseline vs. baseline). Univariate and multivariate regression models were used to analyze the relations
between delays and outcome. Delay cut-offs predicting outcome were determined using ROC-Curves.
Results: In univariate analysis long onset-to-tertiary-hospital time (p = 0.034) was a significant risk factor
for worse-than-baseline condition. Long delays in onset-to-diagnosis (p = 0.032), onset-to-second-stage-
medication (p = 0.023), onset-to-consciousness (p = 0.027) and long total-anesthesia-time (0 = 0.043)
were risk factors for low GOS score (1–3). Short delay in onset-to-initial-treatment (p = 0.047), long
onset-to-anesthesia (p = 0.003) and onset-to-consciousness (p = 0.008) times were risk factors for in-
hospital mortality. Multivariate analysis showed no significant factors.
Cut-offs for increased risk of poor outcome were onset-to-diagnosis 2.4 h (p = 0.011), onset-to-second-
stage-medication 2.5 h (p = 0.001), onset-to-consciousness 41.5 h (p = 0.009) times and total-anesthesia-
time 45.5 h (p = 0.003). The delay over 2.1 h in onset-to-tertiary-hospital time increased the risk of worse-
than-baseline condition (p = 0.028).
Conclusions: GCSE treatment is a dynamic process, where every delay component needs to be optimized.
We suggest that GCSE patients should be handled with high priority and transported directly to hospital
ED with neurological expertise. Critical steps in the treatment, such as diagnosing GCSE and starting
progressive antiepileptic medication on stages 1 through 3, if needed, should be accomplished within
2.5 h.
© 2017 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Status epilepticus (SE) is a life-threatening neurologic emer-
gency situation, which calls for prompt medical treatment to cease
the excessive electric activity in the brain. Incidence of SE varies
from 10 to 20 per 100.0001. Even SE treated with the best medical
practices may result in substantial morbidity and mortality, the
latter ranging from 1.9% to 40% in published studies [1].
SE is an extremely dynamic process and several factors during
this process have been proposed to influence patients’ outcome:* Corresponding author at: Oravatie 12 B, 02270 Espoo, Finland.
E-mail address: leena.kamppi@hus.fi (L. Kämppi).
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1059-1311/© 2017 British Epilepsy Association. Published by Elsevier Ltd. All rights resPatient’s pre-existing characteristics: age, gender, co-morbidities,
pre-morbid functional status; [2–6] Factors related to the current
SE episode: aetiology, SE type, refractoriness, level of conscious-
ness at onset, duration; [4–8] Treatment and complications: Delays
in the treatment, adherence to treatment protocol, anesthetic
treatment, complications [3,6,9–16]. Most of the factors are pre-
existing at the SE onset and cannot be affected, therefore treatment
and complications should be the focus when aiming to improve SE
patients’ outcome.
Time is brain also in SE. Although there is no evidence-based
timeframe for treatment, current guidelines strongly suggest
aggressive and early treatment [17–18]. This approach is supported
by the finding of GABA-A receptor trafficking and internalization
after 30 min of continuous seizure resulting in pharmacoresistanceerved.
Table 1
Description of the material.
Variable N %
Cases 70 100
Patient Characteristics
Age Mean 54,3
Range 16–85
Gender Male 35 50,0
Female 35 50,0
Medical history Previous recorded illnesses 70 100
Epilepsy 46 65,7
Etiologies Epilepsy 46 65,7
Acute brain disorder 7 10,0
Prior brain disorder 7 10,0
Unknown 10 14,3
STESS 2 35 50,0
3 16 22,9
4 10 14,3
5 9 12,9
Refractoriness Non-RSE 8 11,4
RSE 30 42,9
SRSE 32 45,7
Anesthetic treatment No Anesthesia 8 11,4
Propofol only 56 80
Multiple Anesthetics 6 8,6
Outcome Parameters
Condition at discharge Worse-than-baseline 41 58,6
Baseline 29 41,4
GOS at discharge 3 28 40
>3 42 60
Mortality at discharge Yes 5 7,1
No 65 92,9
STESS status epilepticus severity score, RSE Refractory status epilepticus, SRSE
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treatment protocols has been questioned [19], the existing
literature and experts’ opinions strongly emphasize the significant
impact of the quality of treatment on the prognosis of SE [12–13].
The number of published studies regarding delays in the
treatment is relatively low [20] Nevertheless, results from the
recent years show that delays in the treatment and compliance
with suggested protocols are far from optimal, regarding both
adults and paediatric patients [21–22].
Streamlining the treatment protocol after careful evaluation of
the crucial delay components among stroke thrombolysis candi-
dates reduced the in-hospital delay (door-to-needle-time) from
median 105 min to 20 min over the years [23]. Although treatment
of stroke in the early phases is more straightforward than
treatment of SE, similar approaches to optimize SE treatment
could be implemented. First, we should uncover the most
important delay components affecting the outcome and mortality
to define maximum acceptable delays.
This study was designed to find the realistic cut-offs of the
significant delays predicting in-hospital mortality and functional
outcome for protocol streamlining.
2. Material and methods
2.1. Study design and setting
This is a retrospective cohort study performed in Helsinki
University Central Hospital (HUCH), a tertiary hospital serving a
population of 1.4 million. Emergency service in the hospital district
is provided by one tertiary university hospital (HUCH) with
neurological emergency and seven regional hospitals with internal
medicine emergency. The emergency medical service (EMS)
system includes paramedic-, nurse-, and physician-based EMS
units, either ambulance or helicopter. At the time of material
collection second-stage medication was not dispensable by EMS. In
cases of benzodiazepine-resistant SE physician- and nurse-based
EMS units may induce anesthesia and intubate the patient at
emergency site after consulting the physician on shift.
This study conforms to the Finnish legislation concerning
medical research and the permission was granted by the HUCH
Department of Neurology.
2.2. Definition of generalized convulsive status epilepticus/GCSE
The operational definition of established SE being used at the
time of material collection was continuous seizures lasting over
30 min, several recurrent seizures without returning conscious-
ness, or occurrence of more than four seizures within any one hour
irrespective of return of consciousness in between. The definition
of SE has been recently revised24. Patients having a convulsive
seizure at any point of the SE period were considered as having
convulsive SE (CSE). Patients with impaired consciousness, either
primarily or secondarily, were considered as having generalized SE
(GSE).
2.3. Selection of participants
Consecutive adult patients (16 years) diagnosed with
generalized convulsive status epilepticus (GCSE) and treated in
the HUCH emergency department (ED) between January 2002 and
December 2003 were included in the study.
The patients were identified in the HUCH electronic patient
database by the ICD-10 code G41 (SE), yielding a total of 87
patients. Patients not meeting the criteria of GCSE were excluded.
Altogether 70 GCSE patients were eligible for the study.2.4. Data collection
Clinical data were collected by a trained medical doctor from
the original medical records and collected on a standard form
designed for this study. The electronic database was created using
MS Access for data recordings and information of patient
identification was removed before further analyses.
We defined ten specific delay parameters in the management of
GCSE: Onset-to-initial-treatment, diagnosis, second-stage-
treatment, tertiary-hospital, anesthesia, burst-suppression,
seizure-freedom, consciousness, total-anesthesia-time and
total-ICU-time. For determining the accuracy and reliability of
the collected time parameters we calculated The Weighted
Accuracy Score (LWAS) and the Data Availability (DA), using the
method developed for evaluation of retrospective delay materials
[21]. Time points that could not be estimated within the time
window of 30 min were excluded from the analyses and were not
scored with LWAS and DA.
Outcome of the patients was defined as functional outcome and
mortality at hospital discharge. Functional outcome was assessed
with Glasgow Outcome Scale (GOS 1–3 for poor outcome, GOS >3
for good outcome) and condition relative to baseline condition
(worse-than-baseline vs. baseline) at hospital discharge. Outcome
measures at hospital discharge were collected from the medical
records.
Missing events, e.g. no burst-suppression (BS), events happen-
ing during pre-status period, or events with unknown data were
excluded from the final analysis. The missing data information is
presented in online Table 1.
2.5. Definitions of the measures
The onset of GCSE was defined as the beginning of the first
seizure fulfilling the criteria for established GCSE. Initial treatment
was defined as the first antiepileptic drug (AED) given, which wasSuper-refratory status epilepticus, GOS Glasgow Outcome Scale.
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tion was defined as first given second-stage medication. Tertiary
hospital exclusively refers to HUCH ED. The third-stage medication
included anesthesia with propofol, thiopental or midazolam and
induction was considered as the starting point of anesthesia. The
cessation of GCSE was defined with three separate parameters for
the treatment response: BS, clinical seizure freedom and return of
consciousness. BS refers to the beginning of the first BS sequence
during this SE. Clinical seizure freedom refers to the end of the last
clinical convulsion, and return of consciousness refers to the time
point, when the patient no longer presented altered mental status.
Total time of the treatment (anesthesia/ICU) was calculated adding
up the length of all individual anesthesia-/ICU- periods during the
GCSE.
Functional outcome was considered good, if the patient
returned to the baseline condition and GOS at hospital discharge
was >3.
2.6. Statistics
Results are given as mean (SD) or median (interquartile range).
The Mann-Whitney test was used to find out differences in
continuous variables. Logistic regression analysis was used to find
out risk factors/delays for each outcome. Log transformation was
used for time variables in logistic regression analysis. Bootstrap
resampling (1000 samples) was used to calculate bias-corrected
percentile confidence intervals for odds ratios. The receiver
operating characteristics curves were created, and optimal cut-
off values were calculated by maximizing the Yonden’s index. Two-
tailed tests were used and significance was defined as p < 0.05.
Statistical calculations were performed with SPSS (v24, IBM Corp,
New York NY).
3. Results
Patient characteristics, the outcome of the patients and the
delays in the treatment are presented in Tables 1 and 2.
In 69 (98.6%) cases the initial treatment was first-stage
medication, and in only one case it was propofol. For 61 cases
(87,1%) initial treatment was administered pre-hospitally before or
during the transportation to hospital emergency department (ED).
56cases(80%)receiveddiazepam asthe first medicationand13 cases
(18.6%) received lorazepam, average initial doses being 8.2 mg and
2.1 mg respectively. In 26 (37.1%) cases the initial treatment was
administered rectally. 62 cases (88.6%) were medicated with several
doses of first-stage medication before intensifying the treatment to
second- or third-stages, average total dose being 29.5 mg of
diazepam or 6.5 mg of lorazepam. In 35 cases (50%) first-stage
treatment was followed by second-stage medication and the rest, 35Table 2
Delay parameters and the delays in the management of GCSE.
Variable N % TIME 
ALL CASES 70 100 Median 
Delays In The Treatment
Onset-to-initial-treatment 67 95,7 30 min 
Onset-to-diagnosis 70 100 1 h 48 mi
Onset-to-second-stage-medication 67 95,7 2 h 40 mi
Onset-to-tertiary-hospital (HUCH) 70 100 2 h 25 mi
Onset-to-anesthesia 62 88,6 2 h 38 mi
Onset-to-burst-suppression 30 42,9 14 h 42 m
Onset-to-seizure-freedom 70 100 5 h 15 mi
Onset-to-consciousness 61 87,1 42 h 45 m
Total-anesthesia-time 62 88,5 38 h 
Total-ICU-time 63 90 58 h 40 mcases, received directly third-stage medication, which was propofol.
67 of all cases (95.7%) were treatedwith second-stage-medication, in
62 cases (92.5%) it was iv. phosphenytoin and in 5 cases (7.5%) iv.
valproate. Anesthetic treatment was initiated out-of-hospital in 24
(38.7%) of the anesthetized cases. 62 cases (88.6%) were treated with
iv. anesthetics in the ICU department, and all of them received
propofol.
Non-survivors received initial medication median 10 min after
the onset of SE, while the corresponding time for survivors was
three times longer, median 30 min. All the other delays were longer
among non-survivors: onset-to-alarm 4.3 times, onset-to-diagno-
sis 2.5 times, onset-second-stage-medication 1.4 times, onset-to-
anesthesia 3.1 times and onset-to-tertiary-hospital 1.2 times that
of survivors.
GCSE was diagnosed on clinical grounds in 69 (98.6%) cases and
out-of-hospital in 41 cases (39.7%). Diagnostic EEG was required in
one case. 51 (72.9%) of all cases were transferred straight from the
scene to tertiary hospital, the rest of the cases (27.1%) were first
transferred to another hospital ED and later to HUCH ED.
In the univariate logistic regression analysis (Table 3) long delay
in reaching the tertiary-hospital (p = 0.034) was a significant risk
factor for functional deterioration at hospital discharge in relation
to baseline condition. Long delays in onset-to-diagnosis
(p = 0.032), onset-to-second-stage-medication (p = 0.023), onset-
to-consciousness (p = 0.027) and long anesthetic treatment
(p = 0.043) were risk factors for low GOS score (1–3) at hospital
discharge. Short delay in giving the initial AED (p = 0.047), long
delays in starting the anesthesia (p = 0.003) and long delay in
returning consciousness (p = 0.008) were related to risk of in-
hospital mortality.
Onset-to-tertiary-hospital delay was significantly longer
among patients not returning to baseline condition (p = 0.027).
Long onset-to-second-stage-medication, onset-to-anesthesia, on-
set-to-consciousness times and total-anesthesia-time were asso-
ciated with low GOS score (1–3) at discharge (p = 0.007, p = 0.048,
p = 0.032, p = 0.037 respectively), and long delay in onset-to-
anesthesia time was associated with in-hospital mortality
(p = 0.031).
Cut-offs for the significant delays in the univariate analysis
predicting poor/worse-than-baseline condition were determined
by plotting Receiver Operating Characteristic Curves (ROC-Curve)
(Fig. 1, Table 4). Diagnostic delay over 2.4 h (ODDS 3.9, 95%CI 1.4–
11.0, p = 0.011), delay in giving the second-stage-medication over
2.5 h (ODDS 8.3, 95%CI 2.4–28.5, p = 0.001), altered mental status
or unconsciousness prolonging over 41.5 h (ODDS 5.0, 95%CI 1.5-
16.9,p = 0.009) and anesthetic treatment for over 45.5 h (ODDS
5.3, 95%CI 1.8–16.2, p = 0.003) increased the risk of poor
functional recovery (GOS 1–3). Delay over 2.1 h before reaching
the tertiary hospital increased the risk of worse-than-baseline
condition at discharge (ODDS 3.2, 95%CI 1.2–8.8, p = 0.023).MIN MAX DA LWAS
%
0 min 8 h 5 min 97,0 1,8
n 6 min 60 h 6 min 97,1 1,5
n 30 min 61 h 54 min 98,5 1,6
n 37 min 277 h 40 min 98,6 1,5
n 0 min 66 h 20 min 98,4 1,5
in 5 h 5 min 137 h 50 min 100,0 1,5
n 26 min 533 h 15 min 98,6 1,6
in 2 h 40 min 444 h 40 min 96,7 1,4
3 h 35 min 238 h 52 min 98,4 1,1
in 7 h 45 min 520 h 25 min 100,0 1,1
Table 3
Univariate logistic regression analysis of the delays as risk factors for poor outcome at hospital discharge and summary of delay parameters.
Median Time Time 95%CI
Delays time IQR (h) IQR (h) IQR p ODDs Min Max p
Condition At Discharge All Cases Worse-than-baseline Baseline
Onset-to-initial-treatment 0,5 0,8 0,5 0,8 0,6 0,7 0,598 0,9 0,4 1,7 0,721
Onset-to-diagnosis 1,8 2,8 2,0 4,1 1,5 1,5 0,146 2,1 0,6 11,3 0,223
Onset-to-second-stage-treatment 2,7 3,4 3,2 3,9 2,3 2,0 0,087* 2,6 0,5 41,8 0,247
Onset-to-tertiary-hospital 2,4 2,8 2,6 3,5 2,0 2,4 0,027 4,4 1,4 47 0,034
Onset-to anesthesia 2,6 4,0 2,3 4,5 3,2 2,3 0,256 2 0,67 7,7 0,233
Onset-to-Burst-Suppression 14,7 19 14,9 21,8 14,0 19,3 0,632 2,3 0,1 226,8 0,461
Onset-to-seizure-freedom 5,3 46,6 5,8 49,4 4,1 35,4 0,599 1,2 0,7 2,5 0,515
Onset-to-consciousness 42,8 51 56,3 65,3 29,0 43,8 0,082* 2,5 0,8 15,2 0,095*
Total-anesthesia-time 38,0 51,2 46,8 65,6 24,0 29,8 0,059* 3,5 0,9 30,6 0,117
Total-ICU-time 58,7 106,8 67,6 111,4 50,3 90,3 0,106 2,9 0,8 12,2 0,08*
GOS At Discharge GOS 1–3 GOS >3
Onset-to-initial-treatment 0,5 0,8 0,5 1 0,5 0,8 0,966 1,1 0,6 2,2 0,846
Onset-to-diagnosis 1,8 2,8 2,7 4,3 1,5 1,6 0,071* 3,4 1 20,6 0,032
Onset-to-second-stage-treatment 2,7 3,4 3,4 4,6 2,3 2,1 0,007 6,6 1,3 101,5 0,023
Onset-to-tertiary-hospital 2,4 2,8 2,4 4,0 2,1 2,2 0,074* 2,4 0,8 19,7 0,162
Onset-to anesthesia 2,6 4,0 4,3 4,8 2,3 2,3 0,048 3,1 0,92 15,2 0,059*
Onset-to-Burst-Suppression 14,7 19 16,5 33,0 13,3 17,8 0,587 2,3 0,1 44 0,444
Onset-to-seizure-freedom 5,3 46,6 7,5 55,8 4,3 31,3 0,229 1,6 0,8 3,6 0,178
Onset-to-consciousness 42,8 51 59,9 63,8 28,5 43,7 0,032 3,6 1,1 37,7 0,027
Total-anesthesia-time 38,0 51,2 57,9 57,9 26,5 39,5 0,037 5,1 0,9 52,5 0,043
Total-ICU-time 58,7 106,8 69,7 100,1 53,3 109,9 0,114 3 0,8 12,5 0,054*
In-hospital Mortality Dead Alive
Onset-to-initial-treatment 0,5 0,8 0,2 0,8 0,5 0,7 0,115 0,4 0 1,7 0,047
Onset-to-diagnosis 1,8 2,8 4,3 6,5 1,8 2,7 0,208 2,9 0,3 35,5 0,209
Onset-to-second-stage-treatment 2,7 3,4 3,6 4,9 2,6 2,8 0,467 1,4 0 28,2 0,741
Onset-to-tertiary-hospital 2,4 2,8 2,8 49,5 2,3 2,8 0,172 2,6 0,2 7,71E + 75 0,123
Onset-to anesthesia 2,6 4,0 7,5 35,4 2,4 3,7 0,031 8,7 1,2 1,33E + 03 0,003
Onset-to-Burst-Suppression 14,7 19 22,0 18 14,0 19,1 0,22 5,1 0,6 2657,1 0,168
Onset-to-seizure-freedom 5,3 46,6 8,4 92,9 4,7 47,5 0,3 1,8 0,5 51,4 0,252
Onset-to-consciousness 42,8 51 89,3 0 40,4 50,4 0,475 6,3 3,1 30,6 0,008
Total-anesthesia-time 38,0 51,2 76,5 68,3 34,4 48,7 0,202 6,6 0,2 849,8 0,153
Total-ICU-time 58,7 106,8 65,9 115,2 58,6 111,4 0,613 1,8 0,3 15,5 0,463
For logistic regression the variables were log transformed and bootstrapped confidence intervals (CI) were calculated. p values < 0.05 are bolded, p values < 0.01 are marked
with *.
Fig. 1. Receiver operating characteristics curves (ROC-Curves) for the delays. Outcome variable for onset-to-diagnosis, onset-to-second-stage-medication, onset-to-
consciousness and total-anesthesia-time is low GOS score (1–3) at hospital diacharge and for onset-to-tertiary-hospital (HUCH) is worse-than-baseline-condition.
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Table 4
Area under curve (AUC) and cut-offs for the significant delays.
VARIABLES AUC CI 95% CI 95% p CUT-OFF Sens. Spec.
DELAY OUTCOME (min) (Max) (h)
Onset-to-diagnosis GOS 1–3 0,63 0,49 0,77 0,071* 2,4* 0,76 0,56
Onset-to-second-stage-medication GOS 1–3 0,693 0,56 0,83 0,008 2,5 0,59 0,85
Onset-to-tertiary-hospital (HUCH) Worse-than-baseline condition 0,657 0,52 0,79 0,028 2,1 0,71 0,57
Onset-to-consciousness GOS 1–3 0,676 0,54 0,82 0,032 45,4 0,66 0,72
Total-anesthesia-time GOS 1–3 0,658 0,52 0,80 0,037 41,5 0,75 0,64
p values < 0.05 are bolded, p values < 0.01 are marked with *.
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independent risk factors for poor functional outcome at hospital
discharge or for in-hospital mortality (Data not shown).
4. Discussion
This is the first study focussing on the critical delays in the
treatment chain of GCSE associated with mortality and functional
outcome at hospital discharge and determining the delay cut-offs
predicting poor functional outcome. We reveal several relevant
associations between delays and outcome at hospital discharge,
concerning most main components of the treatment chain:
diagnosis, second-stage medication, third-stage medication, ter-
tiary hospital admission and duration of SE. None of the delays
were independently associated with outcome, which illustrates
the dynamic nature of GCSE and elucidates that every delay
component of the treatment chain should be minimized to ensure
optimal outcome. Streamlining the treatment protocol calls for
increased emphasis on the pre-hospital phase of the treatment.
The abundant data available for the great majority of cases and
the good accuracy (Table 2) of records are the strengths of this
study. Accuracy may be a benefit of concurrent systematic training
of EMS personnel for acute stroke thrombolysis treatment
protocol. Additional explanatory factors concerning pre-hospital
setting may be high density of mobile phones and awareness of
emergency actions among laymen.
This study encompasses some limitations related to its
retrospective nature and limited number of patients from a
single tertiary centre. Although this requires some caution in
interpreting the results, retrospective setting expressly elucidates
the realistic difficulties in practical treatment of SE and therefore
enables plausible goal setting for protocol streamlining. Addi-
tionally, all patients in the material have GCSE, which enhances
the homogeneity of the material. Although the material dates
back over several years, it is still representative for present-day SE
management, since during the last decade no major treatment
protocol reformations have been made. Rather, fewer options for
AEDs at the time of material collection and use of phosphenytoin
as the primary second-stage-medication reduce bias due to
heterogeneity of medication selection. The diagnosing and coding
practices were bases on the operational definition and classifica-
tion of SE used at the time of material collection, which likely
explains the relatively high proportion of RSE cases in our
material, as compared to published incidence of RSE. It is
recognized that collection by G41 misses cases diagnosed as SE.
The revised definition of SE [24] is expected to offer a prerequisite
for improved treatment protocol of SE.
4.1. Delays related to outcome
Delayed treatment of SE has beenpreviouslyassociated with poor
prognosis [2,9] and suboptimal or delayed response to medication[25]. Although some reports question the relation between delays
and prognosis [4,26], it is indisputable that prolonged duration of SE
is associated with poor outcome [7–8,27]. Since treatment delays
correlate with longer duration of SE [11,22] and adherence to
treatment protocol improves patients’ outcome [12–13], delays
should be considered as major prognostic factors of SE.
4.2. Initial treatment
Several requirements apply for effective initial treatment of
acutely seizing patients. The most effective medication should be
used, which according to current knowledge is intravenous
benzodiazepine (lorazepam, diazepam, clonazepam) or intramus-
cular midazolam [28–28–29]. Adequate dosing is essential,
because response to under-dosed benzodiazepines might be
falsely interpreted as benzodiazepine-resistance leading to un-
necessary proceeding to higher stage medication [30]. According
to current treatment guidelines the medication should be
administered without delay, within 5 min after seizure onset
[18,31].
During the recent years the knowledge of effective initial
medication has grown and after the RAMPART study [28] the
usage of intramuscular midazolam has increased [32]. Develop-
ment of various administration routes (buccal, intranasal,
intramuscular) has enabled more rapid and socially more
acceptable administration of medications [29]. Pre-filled medi-
cation dispensers might be influential in adequate dosing. In spite
of progress, median treatment delays are still far from optimal
and range from 28 min to several hours [2,9,13,21,22] in public
onset SE cases. This might relate to the fact that delays due to the
patient (i.e. onset-to-alarm delay) are still long and are possibly
difficult to reduce as seen in studies on layman education
campaigns [33]. In addition, only the minority of patients are
treated out-of-hospital [22], which is suboptimal, since pre-
hospital treatment is associated with shorter duration of SE [13].
Although clinical common sense suggests that treatment delay is
essential to SE prognosis [2,9], there are also opposite results
[4,26,34] including the current study, where short delay in giving
the initial medication was associated with increased in-hospital
mortality. This unexpected result could be explained by the
finding that although non-survivors received the initial treatment
significantly quicker than survivors, all the other delays of non-
survivors were multiple, possibly due to greater severity of non-
survivors’ SE and/or their burden of complication [35]. This might
reflect problems in recognition of SE after medication or
erroneuous interpretation of medication response, as proposed
in a pre-hospital study [10]. Because patients in this study
received effective initial medication with adequate doses in a
reasonable time frame, the finding strengthens the idea that all
the other above-mentioned requirements for effective initial
treatment should be met to ensure optimal treatment for SE
patients.
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Current optional medications of SE include intravenous
phosphenytoin, valproate, levetiracetam and lacosamide. The
latter two drugs were not available at the time of our material
collection. This does not influence the conclusions of our study,
since no evidence of any agents’ superiority has been published.
The situation should be reconsidered once the results of the
ongoing randomized ESETT trial comparing phosphenytoin,
valproate and levetiracetam in the treatment of established SE
[36] become available. It is worth noting that in ESETT, patients are
randomized according to the drug, but the delay in drug
application remains uncontrolled.
Only a few studies report the onset-to-second-stage medication
delay. In those studies median delay ranges from 69 min to 3 h [21–
22] and is clearly longer than the guidelines’ suggestion to start
second-stage medication of persisting seizures within 20–40 min
after first-stage treatment [18,31]. Onset-to-second-stage medica-
tion delay is correlated with delay in return of consciousness in
GCSE patients and prolonged time between initial treatment and
second-stage treatment predicts a delayed clinical seizure freedom
and return of consciousness [11]. In the present study, delayed
second-stage treatment, which in most cases was phosphenytoin,
was associated with the risk of poor outcome at hospital discharge.
The predictive cut-off for poor outcome due to delayed second-
stage medication was 2.5 h, which directs the focus of streamlining
the treatment protocol toward pre-hospital phase. These obser-
vations suggest that second-stage medication given already by
EMS and use of newer medications with less storage, monitoring
and safety problems should be considered. However, further
studies are needed, since evidence has been reported that use of
newer AEDs may lower the chance of return to baseline condition
at discharge and result in higher rate of refractoriness [37]. Delays
were not controlled in that study and therefore it is possible that
any second-stage agent given in adequate doses during the first
2.5 h might improve the outcome. Naturally, an adequate
physician’s evaluation is needed to ensure correct diagnosis and
patient safety during the medication. This could be obtained by
recruiting physician-staffed EMS units with high priority for acute
SE cases.
4.4. Diagnosis
As long as SE remains undiagnosed, effective and properly
targeted symptomatic treatment is not started. Consequently,
delay in diagnosis is associated with a higher likelihood of poor
response to treatment and worse outcome [38]. Median diagnostic
delay was over 2 h in a study including all SE types [21], and 45 min
in a study including only GCSE cases [13]. In the current study
including only GCSE patients the diagnostic delay remained under
2 h, mainly due to the fact, that almost all cases could be diagnosed
on clinical grounds. Focal SE is associated with longer diagnostic
delays [10], as is also electrographic SE, whereby availability of EEG
is essential for diagnosis. In a paediatric material, delay of cEEG in
electrographic SE was associated with increased mortality [39].
Our results agree with earlier knowledge by showing that long
diagnostic delay is associated with low GOS score at discharge.
To improve diagnostics of SE, common awareness of the risk of
SE among acutely seizing patients should be increased among
laymen, ambulance dispatchers and paramedics in EMS and
hospital personnel. Even the risk of SE, preferably recognized by
adequate SE detection algorithm, should be handled with highest
priority equal to that used in stroke emergencies. This might imply
sending a physician-staffed unit to the scene not only for
diagnostics, but most importantly for starting adequate treatment
before hospital admission. In order to catch those cases of SE notevident on clinical grounds, attempts should be made to enable
EEG and/or video recordings already at the scene and telemedical
consultation of an epileptologist. Electronic seizure prediction and
detection devices carried by epilepsy patients and connected to
closed-loop warning systems may be useful in selected cases [40],
although it is recognized that in the majority of cases SE occurs in
patients without premorbid epilepsy. Diagnostic improvements
depicted should enhance detection of non-epileptic seizures and
thus prevent potentially harmful overtreatment.
4.5. Tertiary hospital delay
Organization of EMS systems and treatment protocols of SE in
hospital districts vary tremendously throughout the world and
even within countries. There are very few studies comparing
different systems and their effect on patient outcomes. An Italian
study compared patients with SE onset and treatment in urban
versus rural area hospitals and reported significantly higher
mortality in urban areas. The quality of drug treatment signifi-
cantly differed in disfavor of urban area, although the availability of
neurological consultation and EEG were equal [12]. In a small
prospective cohort comparing the outcome of SE patients treated
in tertiary hospital versus regional hospitals, a trend towards
worse outcome in tertiary hospitals was found, although the
groups were equal in age and SE severity (STESS) [41]. In the
current study, a long delay in reaching the tertiary hospital was
associated with worse-than-baseline condition at discharge. This
finding is most likely related to an earlier finding reporting that
transportation directly to tertiary hospital led to quicker diagnosis
and earlier administration of second- and third-stage medications
[10]. We believe that treating SE patients in EDs providing
neurological consultations round-the-clock, as in HUCH ED, and
where EEG is readily available, leads to better prognosis.
The predictive cut-off of little over 2 h in onset-to-tertiary
hospital time calls for prompt recognition of SE and direct
transportation of even suspected SE cases to tertiary hospital.
4.6. Duration of anesthesia and ICU treatments
Initiation of third-stage treatment i.e. intravenous anesthetic
drug treatment (IVAD) is recommended after 30–70 min of
continuous seizure activity, especially in GCSE cases [18,31].
Although some reports propose that IVAD treatment itself might
be harmful for the patients [14], poor prognosis of IVAD treated
patients has mainly been associated with more severe aetiology of
SE, refractoriness and increased number of complications [27]. So
far there are no studies showing the superiority of any particular
IVAD. In a previous report, the delay in starting the IVAD treatment
after the SE onset was median 2 h 55 min [21], whereas in another
study only 37% of the patients were anesthetized within 2 h and
the rest within 24 h [42]. Generalized, convulsive, public-onset SE
cases transported directly to tertiary hospital are more likely to
have short delays in starting anesthesia [10]. Krishnamurthy et al.
suggested that long delay in starting anesthesia does not
necessarily mean poor outcome [5]. We showed otherwise in
the present study, since long delays were associated with higher
in-hospital mortality. Therefore, in cases needing third-stage
treatment, IVADs should be initiated as early as possible after first-,
and second-stage treatments fail, possibly already out-of-hospital.
Reported total anesthesia times vary from median 21.5 h to
several days, depending on the severity and refractoriness of the SE
[15,21,42]. We confirm the previous finding that long anesthesia
time is associated with poor outcome [15] and our study is in line
with the recent report on high mortality of SRSE [43]. IVAD
treatment predisposes to complications, the risk increasing with
time. A trend-like association of total-ICU-time with poor
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Although IVAD treatment exceeding ca. two days predicts poor
functional outcome at hospital discharge, it does not mean that the
IVAD treatment should be limited to two days in all patients. In all
aetiologies other than anoxia continuation of the IVAD treatment
seems reasonable, since even in prolonged refractory SE cases
meaningful functional and cognitive recovery is possible [7].
Targeting IVADs quickly, albeit with strict criteria should prevent
or minimize complications and seems to be essential for improved
prognosis of IVAD treated patients.
4.7. Return of consciousness
Long duration of SE has been associated with poor prognosis
after SE, and the predictive timeframe varies from 1 h to 10 days
[2–3,27]. Since exact endpoint of SE is conceptually problematic
and varies even in the few previous studies that have clearly
defined the endpoint [7,34], we used stepwise definition for the
end of SE, as described in Material and methods section. Still, the
return of consciousness is the only clinically reliable marker for the
end of GCSE. Even the definition regarding the onset of SE seems to
vary in previous studies. This makes comparison with the
previously published results problematic. In the present study
the delay in return of consciousness was related to poor functional
outcome and in-hospital mortality, which is concordant with a
previous study defining the end of SE based on clinical recovery [7].
Little less than two days of unconsciousness seems to be critical for
the prognosis after SE. Burst-suppression delay and onset-to-
seizure freedom delay did not have significant relation to outcome.
The fact that they both are correlated to onset-to-consciousness
delay confirms their position as significant components of the
continuum leading to cessation of SE [11].
5. Conclusions and protocol streamlining suggestions
Streamlining the whole treatment chain of GCSE is necessary.
Every delay component of the treatment should be optimized,
especially in the pre-hospital phase of the treatment. We suggest
that even patients with suspected GCSE should be handled with
high priority by physician-staffed EMS units and transported
directly to hospital EDs with neurological expertise. Critical steps
in the treatment, such as diagnosing GCSE and stepwise initiation
of all stages of antiepileptic medication should be made possible to
accomplish within 2,5 h.
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